蒂尔泽帕提德通过多个分子途径防止神经退行
Rosaria Anna Fontanella1, Puja Ghosh1, Ada Pesapane1
1Department of Advanced Medical and Surgical Sciences, University of Campania "Luigi Vanvitelli", Naples, Italy.
Journal of translational medicine
|January 29, 2024
概括
双重GIP-RA/GLP-1RA的提尔泽帕提德 (TIR) 通过激活关键通路和抵消高葡萄糖的影响,显示神经保护作用. 这为治疗糖尿病相关的认知障碍和神经病变提供了新的希望.
科学领域:
- 神经科学是一个神经科学.
- 内分泌学 在内分泌学.
- 分子生物学分子生物学
背景情况:
- 已知类似葡萄糖1受体激活剂 (GLP1-RAs) 降低了2型糖尿病中痴呆风险.
- 蒂尔泽帕提德 (TIR) 是一种双重依赖葡萄糖的胰岛素托普多受体激动剂 (GIP-RA) /GLP-1RA,具有潜在的神经保护性质.
研究的目的:
- 研究TIR对学习和记忆障碍的保护作用背后的分子机制.
- 阐明TIR对神经元生长,细胞亡,分化和胰岛素抵抗标记物的影响.
主要方法:
- 对TIR对神经元标记物的评估影响 (CREB,BDNF,BAX/Bcl2,pAkt,MAP2等) 在正常和高葡萄糖条件下的SHSY5Y细胞中.
- 研究了TIR在DNA甲基化和特定miRNA中的作用 (34a, 212, 29c).
- 使用Ki-67通过流式细胞计量测量细胞增殖.
主要成果:
- TIR激活了pAkt/CREB/BDNF通路,显示出显著的神经保护功效.
- 在神经元水平上,TIR有效地抵消高血糖和胰岛素抵抗的有害影响.
- TIR 影响表观遗传调节器,促进细胞增殖.
结论:
- 蒂尔泽帕提德可以改善高葡萄糖诱导的神经退行和神经元胰岛素耐药性.
- 这项研究为TIR在治疗糖尿病相关神经病变和认知衰退方面的潜力提供了新的见解.
相关概念视频
Alzheimer's Disease: Treatment
193
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
193
Enzyme-linked Receptors
78.4K
Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
78.4K
Drugs Affecting Neurotransmitter Synthesis
1.4K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.4K
Antidepressant Drugs: MAOIs and Other Agents
234
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
234
Parkinson's Disease: Treatment
268
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
268
Parkinson's Disease: Overview
547
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
547


